Response To: Comment on “New Alternatives for Autoimmune Disease Treatments: Physicochemical and Clinical Comparability of Biosimilar Etanercept”

Journal of Immunology Research - Egypt
doi 10.1155/2018/6156024
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Hindawi Limited

Related search

GP2015: An Etanercept Biosimilar

BioDrugs
MedicineBiotechnologyPharmacology
2017English

Observational Study of Inflammatory Arthritis Treatment by Etanercept Originator Switched to an Etanercept Biosimilar

Reumatologia
RheumatologyAllergyImmunology
2019English

Response To: ‘Mandatory, Cost-Driven Switching From Originator Etanercept to Its Biosimilar SB4: Possible Fallout on Non-Medical Switching’ by Cantini and Benucci

Annals of the Rheumatic Diseases
ImmunologyMolecular BiologyBiochemistryRheumatologyAllergyGenetics
2018English

Real-World Evidence on Etanercept Biosimilar SB4 in Etanercept-Naïve or Switching Patients: A Systematic Review

Rheumatology and Therapy
2019English

Comment on “Psychocutaneous Disease: Clinical Perspectives”

Journal of the American Academy of Dermatology
Dermatology
2017English

SAT0199 Switch From Innovator Etanercept to Biosimilar Etanercept in Inflammatory Rheumatic Diseases: The Experience of Cochin University Hospital Paris-France.

2018English

Comment on "The Influence of the Proinflammatory Cytokine, Osteopontin, on Autoimmune Demyelinating Disease"

Science
MultidisciplinaryPhilosophy of ScienceHistory
2003English

Response to ‘Comment On: Proposal for a New Classification for Ocular Surface Squamous Neoplasia’

Eye
MedicineArtsSensory SystemsOphthalmologyHumanities
2018English

Psy14 - Clinical Response to Systemic Treatments for Steroid-Refractory Chronic Graft-Versus-Host Disease: A Systematic Literature Review

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy